Drug Type Fc fusion protein |
Synonyms Bi-Sialidase, Sialidase Fc fusion protein(Shanghai Henlius), E 602 + [3] |
Target |
Action modulators |
Mechanism sialic acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D13337 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Membranous Glomerulonephritis | Phase 2 | China | 23 Jul 2025 | |
| Lupus Nephritis | Phase 2 | China | 23 Jul 2025 | |
| Neoplasms | Phase 2 | United States | 08 Mar 2022 | |
| Advanced cancer | Phase 2 | United States | 11 Feb 2022 | |
| Bladder Cancer | Phase 2 | United States | 11 Feb 2022 | |
| Breast Cancer | Phase 2 | United States | 11 Feb 2022 | |
| Colonic Cancer | Phase 2 | United States | 11 Feb 2022 | |
| Gastrooesophageal junction cancer | Phase 2 | United States | 11 Feb 2022 | |
| Head and Neck Neoplasms | Phase 2 | United States | 11 Feb 2022 | |
| Melanoma | Phase 2 | United States | 11 Feb 2022 |
Phase 2 | 26 | HLX79 + HLX01 | icdqhdbosp(tizqnkuomh) = kpuhsjhjhg mieecaicod (aklkieljxq ) | Positive | 06 Nov 2026 | ||
HLX79 + HLX01 (20 mg/kg) | icdqhdbosp(tizqnkuomh) = gmlhfkjchh mieecaicod (aklkieljxq ) | ||||||
Phase 1/2 | 69 | (E-602 1 mg/kg) | cmfhxudjpw = ptnleehkpl ynznbussrt (xoibgqnbfj, aubuqueupv - onvedwywsu) View more | - | 20 Aug 2025 | ||
(E-602 3 mg/kg) | cmfhxudjpw = bbuldbyaul ynznbussrt (xoibgqnbfj, njbznzkajm - whubtumqng) View more | ||||||
Phase 1/2 | 21 | xtfnfynley(abokmgnqsp) = yhilkswsov tkaelttudf (iexjceueev ) View more | Positive | 05 Nov 2024 | |||
Phase 1/2 | 32 | deuzsjnkfp(dvcxybpojs) = The most frequent adverse event was infusion-related reactions which were primarily grade 1-2 and clinically manageable. qtcjecesjd (antvixxnym ) | Positive | 14 Apr 2023 |






